| WHO classification of tumours of soft tissue and bone: WHO classification of tumours, vol. 5 C Fletcher, JA Bridge, PCW Hogendoorn, F Mertens World Health Organization, 2013 | 4260 | 2013 |
| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ... The Lancet 364 (9440), 1127-1134, 2004 | 2063 | 2004 |
| Pathology and genetics of tumours of soft tissue and bone CDM Fletcher, KK Unni, F Mertens Iarc, 2002 | 1952 | 2002 |
| Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO JY Blay, S Bonvalot, P Casali, H Choi, M Debiec-Richter, AP Dei Tos, ... Annals of Oncology 16 (4), 566-578, 2005 | 1007 | 2005 |
| IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours MF Amary, K Bacsi, F Maggiani, S Damato, D Halai, F Berisha, R Pollock, ... The Journal of pathology 224 (3), 334-343, 2011 | 990 | 2011 |
| Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ... The lancet oncology 15 (4), 415-423, 2014 | 936 | 2014 |
| Sarcoma derived from cultured mesenchymal stem cells J Tolar, AJ Nauta, MJ Osborn, A Panoskaltsis Mortari, RT McElmurry, ... Stem cells 25 (2), 371-379, 2007 | 800 | 2007 |
| The clinical approach towards chondrosarcoma H Gelderblom, PCW Hogendoorn, SD Dijkstra, CS Van Rijswijk, AD Krol, ... The oncologist 13 (3), 320-329, 2008 | 799 | 2008 |
| Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ... Cancer research 69 (13), 5383-5391, 2009 | 745 | 2009 |
| Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ESMO/European Sarcoma Network Working Group Annals of oncology: official journal of the European Society for Medical …, 2014 | 694 | 2014 |
| Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial PJ Woll, P Reichardt, A Le Cesne, S Bonvalot, A Azzarelli, HJ Hoekstra, ... The lancet oncology 13 (10), 1045-1054, 2012 | 534 | 2012 |
| Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are … J Verweij, A van Oosterom, JY Blay, I Judson, S Rodenhuis, ... European Journal of Cancer 39 (14), 2006-2011, 2003 | 509 | 2003 |
| Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? JK Anninga, H Gelderblom, M Fiocco, JR Kroep, AHM Taminiau, ... European journal of cancer 47 (16), 2431-2445, 2011 | 501 | 2011 |
| Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label … NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ... The Lancet Oncology 17 (10), 1396-1408, 2016 | 447 | 2016 |
| Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study WG Goettsch, SD Bos, N Breekveldt-Postma, M Casparie, RMC Herings, ... European journal of cancer 41 (18), 2868-2872, 2005 | 437 | 2005 |
| Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents EP Buddingh, ML Kuijjer, RAJ Duim, H Bürger, K Agelopoulos, ... Clinical Cancer Research 17 (8), 2110-2119, 2011 | 421 | 2011 |
| Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma … IJ Lewis, MA Nooij, J Whelan, MR Sydes, R Grimer, PCW Hogendoorn, ... Journal of the National Cancer Institute 99 (2), 112-128, 2007 | 418 | 2007 |
| The histopathological differential diagnosis of gastrointestinal stromal tumours JFG van Roggen, MLF Van Velthuysen, PCW Hogendoorn Journal of clinical pathology 54 (2), 96-102, 2001 | 417 | 2001 |
| Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort S Smeland, SS Bielack, J Whelan, M Bernstein, P Hogendoorn, MD Krailo, ... European journal of cancer 109, 36-50, 2019 | 403 | 2019 |
| Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good … SS Bielack, S Smeland, JS Whelan, N Marina, G Jovic, JM Hook, ... Journal of Clinical Oncology 33 (20), 2279, 2015 | 369 | 2015 |
